Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005

Jung‐Min Lee; Mark F. Brady; Austin Miller; Richard G. Moore; Helen Mackay; Leah McNally; Jayanthi Lea; Daron Street; Stéphanie Lheureux; Megan McDonald; Linda Duska; Guilherme Cantuaria; Juraj Kavecansky; Charles A. Leath; Matthew A. Powell; Mark G. Cadungog; Peter G. Rose; Yong‐Man Kim; Helen Q. Huang; Michèle Provencher; Lari Wenzel; Michael A. Bookman; Elise C. Kohn; Angeles Alvarez Secord

doi:10.1200/jco.24.00683

Abstract

We assessed the efficacy of cediranib, olaparib, and cediranib/olaparib compared with standard-of-care chemotherapy (SOC) in platinum-resistant or platinum-refractory epithelial ovarian cancer (PROC).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lee et al. (2024) studied this question.

synapsesocial.com/papers/68e55db1e2b3180350efaff9 https://doi.org/10.1200/jco.24.00683

View at Publisher

Ask AI

Bookmark

Share

Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005

Abstract

Discussion

Cite This Study

Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Journal of Clinical Oncology

Keep reading

More related papers

More from Journal of Clinical Oncology